Why the TAAR1 agonist ulotaront holds promise for schizophrenia
November 22, 2022 · By Brian Buntz · Drug Discovery & Development Ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1)...
A novel phenotypic approach to CNS drug discovery
November 10, 2022 · Drug Discovery World The newest addition to the free DDW podcast is the In Conversation With series, where...
4 next-gen CNS drug development trends
By Brian Buntz · October 24, 2022 · Drug Discovery & Development The past couple of years have had a significant...
Why Psychogenics and Emyria are collaborating to examine MDMA-inspired compounds
By Brian Buntz · Oct 12, 2022 · Drug Discovery & Development CNS-focused contract research organization PsychoGenics has forged a collaboration with clinical-stage...
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
Oct 11, 2022 · Business Wire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and...
Emyria starts program with neuroscience drug discovery CRO
By Jim Cornall · Sept 22, 2022 · Labiotech.eu Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics,...
Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More
By Vanessa Doctor, RN · Sep 22, 2022 · BioSpace It’s been a busy week across the clinical development space, with...